Therefore, our present observations suggest that teneligliptin could inhibit ox-LDL uptake and foam cell formation of macrophages in T1D partly via suppression of CD36 and ACAT-1 expression. The gene discussed is CD36; the disease is type 1 diabetes mellitus.